Oxford Health NHS Foundation Trust

Holmusk and Streamline Healthcare Solutions Announce Strategic Partnership To Bring Behavioral Health Predictive Analytics Tool to US Market

Retrieved on: 
Thursday, June 22, 2023
Mast, National Health Service, Partnership, NHS foundation trust, Smartcar (company), Eye, Mental health, Quality of life, Electronic health record, Patient, EHR, Risk, United Kingdom, Oxford Health NHS Foundation Trust, Health information management, Nursing

NEW YORK, June 22, 2023 /PRNewswire/ -- Holmusk, a leading global behavioral health real-world evidence company, announced today that it is joining forces with one of its strategic partners, Streamline Healthcare Solutions, to enhance care delivery using advanced analytics. The partnership marks the introduction of Holmusk's Management and Supervision Tool (MaST), which is widely used by the National Health Service in the United Kingdom, to a U.S. market.

Key Points: 
  • The partnership marks the introduction of Holmusk's Management and Supervision Tool (MaST), which is widely used by the National Health Service in the United Kingdom, to a U.S. market.
  • MaST is a software platform that uses predictive analytics to help healthcare professionals make decisions, including prioritizing individuals at risk of a mental health crisis.
  • MaST's entry to the U.S. will kick off within Mental Health Partners , a network of behavioral health clinics serving communities across central Colorado.
  • Mental Health Partners already uses Streamline's SmartCareTM Behavioral Health EHR platform, and will be onboarded to using MaST to immediately benefit from data insights provided by the tool.

Sleepio Is the First-Ever Digital Therapeutic to Receive NICE Guidance, Confirming Clinical and Cost Effectiveness

Retrieved on: 
Friday, May 20, 2022
Managed Care, General Health, Health, Mental Health, NHS, Insomnia, Digital, Smartphone, Self-management, National Institute for Health and Care Excellence, CBT, Isabella Tree, Generalized anxiety disorder, Ageing, Regulation of tobacco by the U.S. Food and Drug Administration, Policy, Food, National Institute, Board of directors, Patient, Oxford Health NHS Foundation Trust, CE, UnitedHealth Group, NICE, United Kingdom, FDA, Thames Valley, Anxiety, National Health Service (England), Innovation, Standard of care, Therapy, Innovate UK, Sleep hygiene, Mental health, Lists of diseases, Oxford, Diagnosis, Committee, National Health Service, Web browser, CEO, Pharmaceutical industry, Health insurance, Medical device, Medicine, Sleepio

Peer-reviewed clinical trials show Sleepio helps 76% of patients to achieve clinical improvement in insomnia.

Key Points: 
  • Peer-reviewed clinical trials show Sleepio helps 76% of patients to achieve clinical improvement in insomnia.
  • Big Health co-founder and Chief Scientist Professor Colin Espie said: We are delighted that Sleepio has become the first-ever digital therapeutic to receive NICE guidance after rigorous evaluation.
  • Digital therapeutics arent wellness apps; they are proper treatments backed by data and clinical evidence, fit for assessment by world-leading bodies like NICE.
  • Sleepio is a clinically-evidenced digital therapeutic for insomnia developed by world-renowned clinical psychologist and sleep expert Professor Colin Espie.

OxfordVR Technology a World First Success in Automating Psychological Therapy Using Virtual Reality (VR)

Retrieved on: 
Wednesday, April 6, 2022
Software, Hardware, General Health, Health, Mental Health, Technology, Other Technology, Other Health, Oxford Health NHS Foundation Trust, Cognitive behavioral therapy, Family, Therapy, CBT, University, Delusion, Mental health, Union, Clinical trial, University of Oxford, Agoraphobia, Friends, The Lancet, Psychosis, Lists of diseases, Paranoia, Research, Patient, Hallucination, Schizophrenia, Quality of life, Virtual reality, Technology, Safety, GameChanger, Anxiety, Department, Trust law, Depression, Education, Pharmaceutical industry, Medicine, VR

Users are guided by a virtual coach instead of a real-life therapist, allowing the treatment to reach many more patients.

Key Points: 
  • Users are guided by a virtual coach instead of a real-life therapist, allowing the treatment to reach many more patients.
  • The technology, called gameChangeVRTM is a 6 week, automated, VR treatment that delivers cognitive behavioral therapy (CBT) inside safe, immersive, virtual scenarios.
  • OxfordVR is a digital therapeutics company that develops evidence-based immersive treatments using virtual reality for serious mental illness.
  • OxfordVR is dedicated to improving world class access to mental health, automating gold-standard treatments like cognitive behavioral therapy (CBT).

VitalHub Subsidiary S12 Solutions Reports Two Significant Contracts in September 2021

Retrieved on: 
Tuesday, October 12, 2021
S12, Company, Oxford Health NHS Foundation Trust, Mental health, Efficiency, Case management, Technology, Derbyshire Healthcare NHS Foundation Trust, VHI, Solution, Phrase, Social services, Trust law, Community, Electronic health record, Software, United States Department of Health and Human Services, GLOBE, Traction, Failure, Growth, Regional health authority, Human services, TSX, EHR, Corporation, Emergency Care Coordination Center, CEO, Ministry of Children, Community and Social Services, Risk, Mental Health Act, Home health, Nursing care plan, Section 12 of the Canadian Charter of Rights and Freedoms, MHA, Pharmaceutical industry, Medicine, Risk management

TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- VitalHub Corp. (the Company or VitalHub) (TSX: VHI) is pleased to report that newly acquired subsidiary, S12 Solutions (S12), continues to achieved significant market penetration with two new S12 Solutions contracts signed in September 2021; Oxford Health NHS Foundation Trust(the Trust or Oxford) and Derbyshire Healthcare NHS Foundation Trust (Derbyshire, together, the Trusts).

Key Points: 
  • TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- VitalHub Corp. (the Company or VitalHub) (TSX: VHI) is pleased to report that newly acquired subsidiary, S12 Solutions (S12), continues to achieved significant market penetration with two new S12 Solutions contracts signed in September 2021; Oxford Health NHS Foundation Trust(the Trust or Oxford) and Derbyshire Healthcare NHS Foundation Trust (Derbyshire, together, the Trusts).
  • Both Trusts will utilize the S12 Solution Mental Health Act (MHA) assessment team organization and electronic claims platform.
  • S12 Solutions is a UK-based company, which helps mental health professionals efficiently complete Mental Health Act 1983 (MHA) processes.
  • S12 Solutions is a digital platform with approved section 12 (s.12) doctors for MHA assessments in England, which connects Approved Mental Health Professionals (AMHPs).

Study Demonstrates Combining Digital Therapeutics for Insomnia and IAPT Therapy Improves Sleep, Anxiety, and Depression More Than Therapy Alone

Retrieved on: 
Wednesday, September 1, 2021
Mental Health, Other Health, Health, Science, Research, People, UnitedHealth Group, Sleep, Lists of diseases, Covert conditioning, Research, Food, Health, Ageing, Hospital, University of Oxford, Oxford University Press, Partnership, Employment, University, National Institute for Health and Care Excellence, Therapy, Innovation, Dementia, NHS Long Term Plan, Accreditation, Insomnia, Mental health, Policy, NIHR, Adult, Sleep medicine, National Institute, Regulation of tobacco by the U.S. Food and Drug Administration, Industry, Bath, Self-management, IAPT, Organic, Depression, FDA, Population, Oxford Health NHS Foundation Trust, Isabella Tree, United States Public Health Service, Anxiety, NICE, CBT, NHS, Education, Psychology, Patient, Pharmaceutical industry, Medicine

Additionally, participants using Sleepio reduced their utilisation of high-intensity IAPT treatment, including personalised therapy delivered by mental health professionals.

Key Points: 
  • Additionally, participants using Sleepio reduced their utilisation of high-intensity IAPT treatment, including personalised therapy delivered by mental health professionals.
  • Recovery rates from standardised IAPT measures used to capture symptoms of anxiety (GAD-7) and depression (PHQ-9) were 65 percent for Sleepio users, versus 58 percent in the control group who received IAPT alone.
  • Reflecting on the pandemic, increasingly we'll need more scalable, evidenced digital interventions to augment our services, making care more efficient and effective.
  • Poor sleep is rarely specifically addressed in primary care or mental health services, but clinical evidence shows that insomnia significantly impacts comorbid mental health conditions including depression and anxiety.